PDF(Pubmed)
Abstract：
OBJECTIVE: This study aimed to compare the impact of pre- and postoperative etoricoxib administration versus only postoperative on third molar extraction sequelae and oral health quality of life.
METHODS: This prospective quasi experimental study involved 56 patients, divided into a study group receiving preemptive etoricoxib 120 mg before surgery and postoperative etoricoxib 120 mg (n = 28), and a control group receiving preemptive placebo before surgery and postoperative etoricoxib 120 mg (n = 28). Follow-up assessments were conducted at 3- and 7-days post-surgery, recording swelling, trismus, and adverse events. Patients rated perceived pain using the visual analog scale (VAS) and completed an oral health-related quality of life (OHRQoL) questionnaire at specified intervals. Statistical analysis employed non-parametric tests (i.e., the Mann-Whitney test, Friedman test, and Wilcoxon sign test) with P < 0.05.
RESULTS: Significantly lower VAS scores were reported in the study group throughout the follow-up period (P < 0.05). Pharmacological protocol did not have a significant impact on postoperative edema and trismus (P > 0.05). However, double etoricoxib intake significantly improved postoperative quality of life on day 3 after surgery (P < 0.05).
CONCLUSIONS: Pre- and postoperative etoricoxib 120 mg intake in third molar surgery reduced postoperative pain and enhanced postoperative quality of life on day 3 after surgery. Importantly, it was equally effective in managing swelling and trismus compared to exclusive postoperative intake.
CONCLUSIONS: Preemptive etoricoxib use may decrease patient discomfort following impacted mandibular third molar extraction.
METHODS: This prospective quasi experimental study involved 56 patients, divided into a study group receiving preemptive etoricoxib 120 mg before surgery and postoperative etoricoxib 120 mg (n = 28), and a control group receiving preemptive placebo before surgery and postoperative etoricoxib 120 mg (n = 28). Follow-up assessments were conducted at 3- and 7-days post-surgery, recording swelling, trismus, and adverse events. Patients rated perceived pain using the visual analog scale (VAS) and completed an oral health-related quality of life (OHRQoL) questionnaire at specified intervals. Statistical analysis employed non-parametric tests (i.e., the Mann-Whitney test, Friedman test, and Wilcoxon sign test) with P < 0.05.
RESULTS: Significantly lower VAS scores were reported in the study group throughout the follow-up period (P < 0.05). Pharmacological protocol did not have a significant impact on postoperative edema and trismus (P > 0.05). However, double etoricoxib intake significantly improved postoperative quality of life on day 3 after surgery (P < 0.05).
CONCLUSIONS: Pre- and postoperative etoricoxib 120 mg intake in third molar surgery reduced postoperative pain and enhanced postoperative quality of life on day 3 after surgery. Importantly, it was equally effective in managing swelling and trismus compared to exclusive postoperative intake.
CONCLUSIONS: Preemptive etoricoxib use may decrease patient discomfort following impacted mandibular third molar extraction.
摘要：
目的：本研究旨在比较术前和术后使用依托考昔与术后使用依托考昔对第三磨牙拔除后遗症和口腔健康生活质量的影响。
方法：这项前瞻性准实验研究涉及56名患者，分为研究组，接受术前先发制人的依托考昔120mg和术后依托考昔120mg（n=28），对照组在手术前接受先发制人安慰剂，术后接受依托考昔120mg（n=28）。术后3天和7天进行随访评估，记录肿胀，刺耳,和不良事件。患者使用视觉模拟量表（VAS）对感知的疼痛进行评分，并以指定的时间间隔完成口腔健康相关生活质量（OHRQoL）问卷。统计分析采用非参数检验(即，Mann-Whitney测试,弗里德曼测试,和Wilcoxon符号检验)，P<0.05。
结果：在整个随访期间，研究组的VAS评分显著降低（P<0.05）。药物治疗方案对术后水肿和张口无明显影响(P>0.05)。然而,术后第3天服用双依托考昔可显著改善患者术后生活质量(P<0.05)。
结论：第三磨牙手术前后摄入依托考昔120mg可减轻术后疼痛，提高术后第3天的生活质量。重要的是,与术后独家摄入相比,它在控制肿胀和三联管上同样有效.
结论：抢先使用依托考昔可以减少下颌阻生第三磨牙拔除后患者的不适。
方法：这项前瞻性准实验研究涉及56名患者，分为研究组，接受术前先发制人的依托考昔120mg和术后依托考昔120mg（n=28），对照组在手术前接受先发制人安慰剂，术后接受依托考昔120mg（n=28）。术后3天和7天进行随访评估，记录肿胀，刺耳,和不良事件。患者使用视觉模拟量表（VAS）对感知的疼痛进行评分，并以指定的时间间隔完成口腔健康相关生活质量（OHRQoL）问卷。统计分析采用非参数检验(即，Mann-Whitney测试,弗里德曼测试,和Wilcoxon符号检验)，P<0.05。
结果：在整个随访期间，研究组的VAS评分显著降低（P<0.05）。药物治疗方案对术后水肿和张口无明显影响(P>0.05)。然而,术后第3天服用双依托考昔可显著改善患者术后生活质量(P<0.05)。
结论：第三磨牙手术前后摄入依托考昔120mg可减轻术后疼痛，提高术后第3天的生活质量。重要的是,与术后独家摄入相比,它在控制肿胀和三联管上同样有效.
结论：抢先使用依托考昔可以减少下颌阻生第三磨牙拔除后患者的不适。
